Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of Hisun anti-CD20 antibody plus CHOP versus rituximab plus CHOP in untreated diffuse large B-cell lymphoma
ChiCTR2100042104Phase 2Completed
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of rituximab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Overall response rate. Started Jun 2016; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2100042104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042104.